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EDITORIAL
Pharmacologic intervention in urinary tract obstruction—
Is it possible?
Characteristically, urinary tract obstruction in humans
is associated with progressive hydronephrosis, parenchy-
mal atrophy, and impairment of renal functions. At
present, it is neither possible to predict the functional
changes of a hydronephrotic kidney nor the changes in
kidney function after surgical relief of an obstructed kid-
ney. The question therefore arises whether kidney func-
tion would benefit from pharmacologic treatment as an
adjunct to surgery in this complex disorder? In the unilat-
eral ureteral obstruction (UUO) model of experimental
hydronephrosis in rats the pathophysiology is character-
ized by profound changes in renal hemodynamics, tubular
functions, and progressive interstitial fibrosis [1]. Many
processes are involved in the renal tubulointerstitial re-
action that occurs after unilateral ureteral obstruction.
Importantly, there are tubular apoptosis and cellular in-
flammatory changes with macrophage infiltration and the
presence of interstitial fibroblasts, preceded by increased
tumor necrosis factor-a expression, which stimulates pro-
duction of chemoattractant factors, including monocyte
chemoattractant protein-1 [1]. The macrophages are ca-
pable of releasing potent peptide growth factors, includ-
ing transforming growth factor-b1 (TGF-b1), which plays
a major role for matrix protein overproduction in obstruc-
tive nephropathy.
Numerous studies have demonstrated that angiotensin
II (Ang II) plays a pivotal role for the pathogenesis in
obstructive nephropathy likely initiating the cascade of
pathophysiologic changes in kidney functions and kid-
ney damage. Essentially, the angiotensinogen gene, which
provides the precursor for angiotensin production is stim-
ulated by nuclear factor-jB (NF-jB) activation, which is
activated by Ang II production in the liver and kidney
[2]. Hence, this provides an autocrine (vicious) reinforc-
ing loop that up-regulates intrarenal Ang II production,
which can be partly prevented by angtiotensin-converting
enzyme (ACE) inhibition or Ang II type 1 (AT1) receptor
antagonist treatment [2].
Key words: obstructive nephropathy, nitric oxide.
C© 2005 by the International Society of Nephrology
Protection from obstruction induced detrimental ef-
fects on renal function can also be achieved by nitric
oxide (NO) supplementation. This can either be accom-
plished by ACE inhibition, which increases kinin levels
and subsequently increases NO formation, or by stimula-
tion of endogenous NOS with L-arginine [3]. L-arginine
is a semi-essential amino acid and is also substrate and
the main source for generation of NO via NO synthase
(NOS) [4]. Importantly, chronic UUO in mice leads to
significant reduction in inducible (i)NOS activity and the
obstructed kidney of iNOS knock-out mice exhibited sig-
nificant more apoptotic renal tubules than controls, un-
derscoring the important role NO plays for protecting the
cellular functions in the obstructed kidney [5].
In the present issue of Kidney International, Ito et al
demonstrate that dietary L-arginine supplementation
attenuates renal damage of a 3-day unilateral ureteral
obstruction in rats examined at 7 days after relief of the
obstruction [6]. This paper follows a series of elegant con-
tributions from this group, highlighting the role of the
NO system in obstructive nephropathy. L-arginine ad-
ministration increases renal NO production, and in the
present study, this was evidenced by an increase in uri-
nary NO2/NO3 ratio. Previously, it was demonstrated in
separate studies that NO has protective effects on renal
function [7], interstitial fibrosis [3], and tubular apoptosis
[8]. The beauty of the present study is the combination
of detailed examinations of renal function and analysis
of cellular and histologic changes—a so-called molecu-
lar physiology approach. Moreover, the authors deserve
credit for examination of the changes in kidney function
after relief of obstruction.
The elegant manipulation with the NO system in the
present experiments using L-arginine, L-NAME, and the
combination of the L-arginine and L-NAME generated
an array of results that confirm that NO is crucial for
maintaining renal function after relief of UUO, and bring
novel information regarding regulation of the pathophys-
iologic changes in UUO. By dietary supplementation with
L-arginine from 15 days prior to UUO, the present paper
provides substantial evidence that additional NO sub-
strate may be beneficial for the improvement of renal
damage in the post-relief period. Moreover, the present
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experiments demonstrate that baseline levels of NO may
be sufficient to prevent some of the changes, since block-
ade of NO with L-NAME resulted in a significantly
increased amount of interstitial fibrosis. In addition, L-
arginine treatment attenuated apoptosis in the tubular
cells, whereas this was exacerbated by L-NAME demon-
strating that NO is antiapoptotic both during and after re-
lief of obstruction. L-arginine also significantly decreased
macrophage infiltration and the number of fibroblasts
present in the kidney 7 days after relief, indicating
that NO prevents renal damage. The potential role of
epithelial mesenchymal transition (EMT) being respon-
sible for the increased number of fibroblasts in the post-
obstructed kidney and how this is regulated may have
significant pathophysiologic implications. As recently
suggested, EMT-derived fibroblasts may facilitate imme-
diate repair of injury and potentially serve as a pool of
vital cells with the capacity to repopulate the injured
tubular epithelium [9]. The finding that L-arginine did
not alter tissue levels of the profibrotic cytokine TGF-b1
may seem surprising. As mentioned above, an enhanced
intrarenal angiotensin II generation in the UUO kidney
may activate NF-jB, indirectly controlling TGF-b1 ex-
pression because NF-jB regulates the promoter of trans-
glutaminase, which is an activator of latent TGF-b1 [10].
The increased level of TGF-b1 in the contralateral kidney
after relief of obstruction is consistent with previous find-
ings [11], which were not prevented by L-arginine treat-
ment. Despite that, the compensatory increase in GFR
was prevented, indicating that L-arginine may prevent
renal damage in the contralateral kidney.
The present study indicates that L-arginine treatment
may be a pharmacologic-useful avenue to enter in ob-
structive nephropathy. However, although L-arginine
has proven to prevent kidney function impairment and
renal damage at the molecular level in rats with obstruc-
tive nephropathy, and may be well tolerated, many unan-
swered questions with regard to the role of NO remain
to be addressed before L-arginine can be used in clinical
trials in obstructive nephropathy. How is NO preventing
macrophage recruitment to renal interstitium? NO has
been shown to cause apoptosis. Thus, this may directly
influence the reduction in macrophages. Because TGF-
b1 and bone morphogenetic protein-7 (BMP-7) seem to
have opposing actions in the development of renal inter-
stitial fibrosis [9], the role of NO for renal BMP-7 ex-
pression and the intracellular pathways involved, as well
as the role of EMT, in obstructive nephropathy need to
be defined. The present study nicely demonstrated pre-
vention of the impaired renal function 7 days after relief
of obstruction, but it is important to examine the long-
term consequences of treatment. Finally, from a clinically
point of view, a major challenge is to define the effects of
treatment at the time when a UUO kidney is released.
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